Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2500 participants.

Also called NCT07232030

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 2,500 participants (planned count) (from the registry)
Sponsor
CVRx, Inc. (from the registry)
Registry
  • NCT NCT07232030
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07232030. Randomized; no masking; primary purpose treatment. Start 2026-04-24 (actual); primary completion 2033-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
Acronym
BENEFIT-HF
Condition
Heart Failure
Condition
Heart Failure NYHA Class II
Condition
Heart Failure NYHA Class III
Intervention (Device)
Barostim System
Intervention (Other)
Usual care medical management
Lead sponsor
CVRx, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07232030
Content hash
7bbe2af4113ecc9fa2a392dcf3a35d1adec557265e6a28c69ee597b28e8f5304